Latest news with #DERM
Reuters
12 hours ago
- Health
- Reuters
Affidea Partners With Skin Analytics to Improve Access to Skin Cancer Assessment Across Europe Using AI Technology
THE HAGUE, Netherlands, August 18, 2025 (EZ Newswire) -- Affidea, opens new tab, a leading pan-European provider of community-based polyclinics, advanced diagnostics, and multi-specialist care, including oncology, has entered a strategic partnership with Skin Analytics, opens new tab, a pioneering AI company in dermatology care. This collaboration supports Affidea's long-term vision of leveraging digital innovations to improve patient outcomes as part of its integrated skin cancer care pathway. As part of this partnership, Affidea has implemented Skin Analytics' DERM, an AI medical device software for the automated analysis of skin lesions. The initial implementation of DERM began in Romania and Lithuania, with Greece to follow in September. These countries were selected based on market analysis, clinical readiness and innovation focus. The aim is to improve patient access to high quality care by introducing clinically validated AI technology into the gold standard skin care pathway already in place. This enables patients' triage while streamlining workflows. Following this first phase, Affidea plans to roll out the AI solution across additional European markets. Dr. Charles Niehaus, executive director for Affidea Group, stated: "Integrating cutting-edge digital innovations into clinical practice is essential to delivering the best possible care for our patients. Our partnership with Skin Analytics marks an exciting milestone, enabling us to leverage AI in supporting early detection of skin cancer and to provide even more patients with access to the prevention, diagnosis, and treatment programs we already offer in our dermatology units. This collaboration is not just about introducing new technology — it's about creating scalable, sustainable solutions that empower patients and clinical teams, address rising demand and bring timely, high-quality care across Europe." Neil Daly, founder and CEO of Skin Analytics, stated: 'We're incredibly proud to be partnering with Affidea as our first European partner. This collaboration represents a major milestone in our mission to transform access to dermatology care using AI. By combining Affidea's clinical excellence and pan-European reach with our proven technology, DERM, we have an opportunity to reimagine how skin cancer is identified and managed across the continent. At scale, this partnership will drive earlier diagnoses, improve access to care and support dermatology teams facing rising demand — ultimately marking history for how skin cancer care is delivered and improving outcomes for patients across Europe.' Skin cancer remains a significant public health challenge across Europe. According to GLOBOCAN 2022 data, Europe accounts for approximately 10.4 melanoma cases per 100,000 people. Non-melanoma skin cancers were even more prevalent, with over 1.15 million cases in Europe in 2022 [1]. This burden continues to grow — age-standardised incidence rates for melanoma have risen sharply over the past decades, and non-melanoma cases now represent nearly 78% of all skin cancer diagnoses. Source [1] Global Cancer Observatory, International Agency for Research on Cancer: opens new tab About Affidea Group Affidea is a leading pan-European provider of specialist healthcare services, including cancer care, community-based polyclinics and advanced diagnostic imaging. Founded in 1991, the company operates over 410 centres across 15 countries, with more than 14 million patient visits every year. Affidea is majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on long-term value-creation with a stable and supportive family shareholder base. For more information, visit opens new tab. For media inquiries regarding Affidea Group, contact opens new tab. About Skin Analytics Skin Analytics was founded in 2012 by Neil Daly to help more people survive cancer. It began providing teledermatology services in 2015 and since 2020 is now deployed in 27 NHS sites across the UK, having seen more than 180,000 NHS patients and detected more than 15,500 cancers. Post-market surveillance has shown that DERM found 97% of cancers (and accurately identified over 75% of benign lesions) with a negative predictive value (NPV) of 99.6% for all skin cancers. Settings in which DERM has been deployed have been able to reduce the number of face-to-face dermatologist appointments required for the volume of suspected skin cancer referrals by 60 to 95%, and DERM can autonomously discharge up to 40% urgent suspected skin cancer referrals. DERM is the only Class III CE marked AI Dermatology medical device, enabling Skin Analytics to begin actively expanding its lifesaving services to Europe. For more information, visit opens new tab. For media inquiries regarding Skin Analytics, contact skin@ opens new tab. About DERM DERM is an AI medical device (AIaMD), operating under a Class III CE mark. DERM is intended for use in the screening, triage and assessment of skin lesions suspicious for skin cancer. DERM will analyse a dermoscopic image of a skin lesion and return a suspected diagnosis and, if applicable, a referral recommendation for the lesion. DERM is indicated for use on dermoscopic images of cutaneous lesions where there is a suspicion of skin cancer in patients aged 18 years or over in any body location except where specific exclusions apply. Deployed across NHS sites in the UK, Skin Analytics pathways have seen more than 180,000 patient cases and supported the identification of over 15,500 cancers. With a negative predictive value rate of 99.9% for ruling out melanomas, the platform has become a proven tool for aiding clinical decision-making while enhancing patient access and efficiency within skin cancer pathways. Media Contact Oana ### SOURCE: Affidea Group Copyright 2025 EZ Newswire See release on EZ Newswire
Yahoo
05-08-2025
- Business
- Yahoo
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ('Journey Medical' or the 'Company') (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ('FDA')-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025 financial results after the U.S. financial markets close on Tuesday, August 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Tuesday, August 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to Please note that registered participants will receive their dial-in number upon registration. A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical's website, and will remain available for replay for approximately 30 days after the conference call. About Journey Medical CorporationJourney Medical Corporation (Nasdaq: DERM) ('Journey Medical') is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology's most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical's common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission ('SEC'). For additional information about Journey Medical, visit Company Contact:Jaclyn Jaffe Journey Medical Corporation(781) 652-4500ir@ Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@ 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
16-06-2025
- Health
- Yahoo
Warrington Hospital to use AI to speed up diagnosis of skin cancer
AI technology will be used to speed up the diagnosis of skin cancer in Warrington. Bridgewater Community Healthcare NHS Foundation Trust and Warrington and Halton Teaching Hospitals NHS Foundation Trust say this will provide patients with a swifter diagnosis of skin cancer. The service is located at Warrington and Halton Diagnostics Centre which is located at Halton Health Hub, within Runcorn Shopping City. Penketh resident Stephen Champion has already used the service. Speaking about his experience, he said: 'I was amazed by the speed of the AI. The fact that you get seen and diagnosed within minutes rather than having to book a follow-up appointment, was great. The staff there were brilliant too, very friendly and explained clearly what was going on. 'In terms of where the service is, because you're at a shopping centre, I didn't have to pay for parking and there's plenty of it too. It was all seamless.' Stephen Champion (Image: Supplied) The use of AI comes as a rise in skin cancer referrals is resulting in a high demand for dermatology services across NHS organisations. Since 2022, the dermatology service (which is run by Bridgewater Community Healthcare) is now averaging over 300 patient referrals per month, with approximately half resulting in further testing and treatment into conditions such as skin cancer. This new NHS partnership with artificial intelligence technology provider Skin Analytics uses 'cutting-edge, NICE-recommended AI' by recognising cancerous, pre-cancerous and common harmless skin conditions through photographic images. Resulting in faster diagnosis, this 'state-of-the-art' system called DERM, is impressively 99.9 per cent accurate when ruling out melanoma and 97 per cent sensitive when detecting skin cancer. When visiting the service, which is for patients who are 18 years and over and have been referred by their local GP, patients have images taken of their mole or skin lesion at a dedicated 'Photo Hub Clinic'. These are then inputted into the DERM system and assessed using AI. Those with common harmless skin conditions are quickly discharged without having to see a consultant. If, however, the DERM system flags any skin lesions as potentially pre-malignant or malignant, the patient will receive faster access to care, with some treatment performed on the same day, at the same location. Acting as a 'one stop clinic', not only is the service a first of its kind across the NHS Cheshire and Merseyside region. Warrington and Halton Diagnostics Centre, a service provided by Warrington and Halton Teaching Hospitals, is located at Halton Health Hub, within Runcorn Shopping City. This is one of only a small number of NHS community diagnostic centres to be launched inside a shopping centre in the country, and as such is another first for the NHS Cheshire and Merseyside region. Dr Paul Fitzsimmons is joint medical director for Bridgewater Community Healthcare and Warrington and Halton Teaching Hospitals. He said: "Skin cancer is the most frequently referred cancer specialty within the NHS, and we're experiencing this increase firsthand across Warrington. 'The rise in suspected skin cancer referrals has been placing increased pressure on our dermatology service. 'To better manage this growing demand, the partnership we have created with Skin Analytics has offered a valuable opportunity to work creatively by using effective, cutting-edge AI healthcare innovation. 'Not only does this AI technology speed up diagnosis and possible on the day treatment; the fact the service is located, not in a hospital but inside a modern diagnostic facility within a shopping centre, showcases how healthcare is able to reach out into our local communities.' Dan Mullarkey, medical director at Skin Analytics said: 'At Skin Analytics, we believe every patient deserves access to fast and effective skin cancer diagnosis. 'With DERM, NHS organisations receive a flexible and transformative solution for dermatology services that brings care directly to the community. 'By establishing this service within a shopping centre, expert dermatological care is conveniently accessible where people already live, work, and shop. 'It's wonderful to see local NHS trusts embracing innovation that eliminates traditional barriers to healthcare access, and together, we'll improve the patient journey for those with suspected skin cancer by providing timely care in familiar, convenient locations."
Yahoo
15-05-2025
- Business
- Yahoo
Journey Medical Corp (DERM) Q1 2025 Earnings Call Highlights: Amrosi Launch Boosts Margins ...
Net Revenue: $13.1 million for Q1 2025, compared to $13 million for Q1 2024. Amrosi Revenue: $2 million from the initial launch included in Q1 2025 net product sales. Gross Margin: Increased to 64% in Q1 2025 from 54% in Q1 2024. R&D Costs: Nil in Q1 2025, compared to $7.9 million in Q1 2024. SG&A Expenses: Increased to $10.6 million in Q1 2025 from $8.4 million in Q1 2024. Net Loss: $4.1 million or $0.18 per share for Q1 2025, compared to $10.4 million or $0.53 per share for Q1 2024. Cash Position: $21.1 million at the end of Q1 2025, compared to $20.3 million at December 31, 2024. Commercial Payer Access: Approximately 30% of covered commercial insured lives now have access to Amrosi. Warning! GuruFocus has detected 8 Warning Signs with DERM. Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Journey Medical Corp (NASDAQ:DERM) successfully launched Amrosi, a new oral rosacea treatment, contributing $2 million to the first quarter 2025 net product sales. The company reported a gross margin increase to 64% in Q1 2025, up from 54% in the prior year, due to a favorable product sales mix and reduced product costs. Amrosi's market introduction has been well-received, with positive feedback from healthcare providers and strong initial prescription volumes. Approximately 30% of commercially insured lives now have access to Amrosi, up from 20% in the previous quarter, indicating progress in payer coverage. The inclusion of Amrosi in the National Rosacea Society's treatment algorithms and its publication in JAMA Dermatology are expected to drive further clinical adoption and market uptake. Net revenue for Q1 2025 was only slightly higher at $13.1 million compared to $13 million in Q1 2024, indicating limited overall revenue growth. Legacy products experienced a decline, with a noted decrease in prescriptions for Accutane due to increased competition and aggressive pricing by new market entrants. SG&A expenses increased by $2.1 million to $10.6 million in Q1 2025, reflecting higher investments in commercial infrastructure for the Amrosi launch. The company reported a net loss to common shareholders of $4.1 million for Q1 2025, although this was an improvement from the $10.4 million loss in Q1 2024. There is uncertainty regarding the sustainability of initial Amrosi sales, as the Q1 revenue included significant stocking, and future revenues will need to reflect actual demand. Q: Can you provide insights on the Q1 revenues for Amrosi and expectations for future quarters? A: Claude Maraoui, President and CEO, explained that the $2 million in Q1 revenues was largely due to stocking the distribution channel. The salesforce began actively promoting Amrosi in April, and while no specific revenue expectations for Q2 were provided, the company is optimistic about continued growth and will share updates at the end of Q2. Q: How is the legacy business performing, particularly with products like Cubrexa and Accutane? A: Claude Maraoui noted a decline in legacy brands due to generic competition. However, Cubrexa is performing well, with a 15% increase in prescriptions year-over-year, despite new competition. Accutane faced challenges from new competitors but showed a 10% growth from Q4 2024 to Q1 2025, indicating stabilization. Q: What is the current inventory level in the distribution channel, and how do you anticipate it changing? A: Claude Maraoui stated that the inventory level is typically between 2 to 4 weeks, depending on the ramp-up. The company is focusing on specialty pharmacies that dermatologists frequently use, and the inventory level will adjust as demand grows. Q: What feedback have you received from prescribers about Amrosi, and who are the primary prescribers? A: Claude Maraoui shared that feedback has been positive, with prescribers impressed by Amrosi's efficacy and tolerability. The initial focus is on new patients, with expectations that prescribers will switch existing patients to Amrosi as they gain confidence in the product. Q: Is there any feedback from doctors regarding Amrosi's impact on erythema, even though it's not in the label? A: Claude Maraoui mentioned anecdotal feedback from doctors noting significant erythema reduction, which is supported by data published in JAMA Dermatology. The company plans to build on this data to inform providers about Amrosi's impact on erythema. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
01-05-2025
- Health
- Yahoo
New AI tool to spot skin cancer to be used in NHS
Adults with suspected skin cancer may be initially assessed with a new AI tool after it was approved for NHS use. The National Institute for Health and Care Excellence (Nice) said that the technology, which has been conditionally approved for the next three years, has the potential to reduce waiting times. It comes as health experts issued a warning over sun cream ahead of the Bank Holiday weekend. Melanoma Focus said a large proportion of Britons are frequently letting themselves burn, putting themselves at a higher risk of deadly skin cancer. The new artificial intelligence (AI) tool, DERM (Deep Ensemble for Recognition of Malignancy), works by analysing images of moles or skin lesions to see whether they are potentially cancerous. The tool, developed by Skin Analytics, can be used by healthcare workers who use a smartphone with a high quality magnifying lens attached, also known as a dermoscopic lens, to take images of suspicious moles, or skin lesions. The images are then uploaded on to DERM's online platform, which uses AI to analyse the images. For patients whose moles or lesions are identified as potentially cancerous, a specialist skin doctor, known as dermatologist, will review the case and come up with a plan for the patient. People whose moles or lesions are not suspicious are either offered reassurance and advice or can be put on a 'non-urgent pathway'. Nice said that early evidence suggests the automated use of the tool could 'approximately halve the number of referrals to dermatologists within the urgent skin cancer pathway'. It has been 'conditionally approved' for the next three years, while further evidence is collected, Nice said. 'DERM has shown promising results in its ability to accurately distinguish between cancerous and non-cancerous skin lesions, with evidence suggesting it could halve the number of referrals to dermatologists within the urgent skin cancer pathway while maintaining patient safety,' said Dr Anastasia Chalkidou, healthtech programme director at Nice. 'Our evaluation shows this technology maintains diagnostic accuracy while reducing the burden on specialist dermatology services. By implementing this system within existing pathways, we can ensure patients get the right care more quickly.' Ashley Dalton, minister for public health and prevention, said: 'By embracing the power of AI, this exciting technology could help us slash waiting times — meaning that people with suspected skin cancer get the help they need, or peace of mind, faster.' Neil Daly, chief executive of Skin Analytics said: ''We're incredibly proud of the work we've been doing with the NHS over the last five years to achieve this recommendation from Nice. Having seen more than 165,000 patients and found more than more than 15,500 cancers since launching, we are ready to make our Class III autonomous skin cancer AI available to more UK patients.' The British Association of Dermatologists said in a statement: 'Until further evidence is generated, the British Association of Dermatologists recommends that all patients should have some input from a dermatologist. 'Implementation of AI must be underpinned by patient safety, with a clear understanding of the benefits and limitations.' The Association said that AI has 'the potential to transform dermatology services' but said that more real-world evidence is needed. It comes as Melanoma Focus warned about the dangers of sunburn among Britons. 'It is essential that everyone understands the risks associated with sunburn and prioritises sun protection by using factor 30+ sunscreen, wearing a hat, seeking shade and covering up in the heat of the day,' said Susanna Daniels, chief executive of Melanoma Focus. A poll by Melanoma Focus of 2,000 people aged 16 and over in the UK that almost half (49%) said they are sunburned at least once a year, with higher numbers reported in younger age groups. Ms Daniels added: 'This data is extremely concerning as we know that more than five sunburns in your lifetime doubles your risk of melanoma, so burning every year has potentially long-term dangerous consequences. 'Nearly nine in 10 melanomas are preventable, yet the UK has more deaths from melanoma per year than Australia.' The poll also found that 19% said they 'rarely' wear sun cream in the UK between May and September, 8% said they 'never' use sun cream in the UK during this period. Almost one in 10 (9%) said they never wear sun cream at all. Reasons for avoiding sun cream in the UK included people not expecting to burn; forgetting to apply sun cream and 8% said sun cream is 'too expensive'. Sign in to access your portfolio
